<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103969</url>
  </required_header>
  <id_info>
    <org_study_id>POLE COHORT</org_study_id>
    <nct_id>NCT05103969</nct_id>
  </id_info>
  <brief_title>Cohort of Tumors With POLE/D1 Mutation</brief_title>
  <official_title>Multicenter Prospective Cohort of Tumors With Pole/D1 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of this study is to identify and describe the clinico-biological and&#xD;
      molecular characteristics of tumors with somatic POLE (Polymerase ɛ)/POLD1 mutation&#xD;
      identified by molecular biology platforms for all stages and primary sites combined&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The identification of patients to be included will be done directly from the tumor genotyping&#xD;
      platforms.&#xD;
&#xD;
      Indeed, they will be the direct source of the identification of all POLE (Polymerase ɛ)&#xD;
      mutations.&#xD;
&#xD;
      The platforms will inform the project coordination unit of new cases of mutated cancers as&#xD;
      well as the referent investigator, jointly they will be in charge of data entry.&#xD;
&#xD;
      The diagnostic and follow-up data of each patient will be collected prospectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2021</start_date>
  <completion_date type="Anticipated">October 6, 2027</completion_date>
  <primary_completion_date type="Anticipated">October 6, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To identify and describe the clinico-biological and molecular characteristics of tumors with somatic POLE/POLD1 mutation identified by molecular biology platforms for all stages and primary sites</measure>
    <time_frame>October 2027</time_frame>
    <description>Collection and description of clinical and histo-pathological data of tumors with POLE/POLD1 mutation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular characterization of the identified POLE/POLD1 mutations</measure>
    <time_frame>October 2027</time_frame>
    <description>Molecular characterization of the identified POLE/POLD1 mutations and of the mutational profile associated with these mutations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival and response to treatments</measure>
    <time_frame>October 2027</time_frame>
    <description>Analysis of overall survival and response to treatments (chemotherapies, immunotherapies...)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>database and block librabry</measure>
    <time_frame>October 2027</time_frame>
    <description>Establishment of a database of somatic POLE variants Establishment of a block library of POLE mutated tumors</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Tumors</condition>
  <condition>POLE Exonuclease Domain Mutation</condition>
  <condition>POLD1 Gene Mutation</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blocks of tumor removed in the course of care fixed tissue.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        - Patient with a histologically proven tumor with a POLE or POLD1 mutation identified by&#xD;
        molecular biology analysis, carried out within the framework of clinical practice in the&#xD;
        platforms that have set up this research.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any tumor presenting a variant of the exonuclease domain of POLE (exons 9 to 14)&#xD;
             classified as pathogenic by the project working group, including: the 4 hotspots of&#xD;
             mutations described (codons 286 (P286R/H/L), 411 (V411L), 459 (S459F), 424 (L424/V/I),&#xD;
             (2).&#xD;
&#xD;
          -  Any tumor presenting a variant of the exonuclease domain of PolD1 (exons 8-12),&#xD;
             classified as pathogenic by the project working group, including : C319Y(10).&#xD;
&#xD;
        Diagnosis made from the date of launch of the cohort and in the previous year&#xD;
&#xD;
        -Age ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor without POLE or POLD1 mutation&#xD;
&#xD;
          -  Tumor with POLE mutation identified in research studies retrospective research&#xD;
&#xD;
          -  Opposition of the patient to the registration of his data in the cohort&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosine GUIMBAUD, PhD.MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fédération francophone de Cancérologie digestive</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ROSINE GUIMBAUD, PhD.MD</last_name>
    <phone>+33 (0)5 61 32 21 42</phone>
    <email>guimbaud.r@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU -hopital Rangeuil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosine GUIMBAUD, PhD MD</last_name>
      <phone>+33 (0)5 61 32 21 42</phone>
      <email>guimbaud.r@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

